James Chan

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi Differential association between statin exposure and elevated levels of creatine kinase
    James Chan
    Pharmacy Outcomes Research Group, Pharmacy Operations, Kaiser Permanente Medical Care Program, Oakland, CA 94612 3429, USA
    Ann Pharmacother 39:1611-6. 2005
  2. ncbi Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population
    James Chan
    Pharmacy Outcomes Research Group, Pharmacy Operations, Kaiser Permanente Medical Care Program, Oakland, Calif 94612, USA
    Am J Manag Care 10:433-41. 2004
  3. ncbi Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids
    James Chan
    Pharmacy Outcomes Research Group, Kaiser Permanente Medical Care Program, 1800 Harrison, 13th Fl, Oakland, CA 94612, USA
    J Manag Care Pharm 13:21-7. 2007
  4. ncbi Effect of cost-sharing changes on self-monitoring of blood glucose
    Andrew J Karter
    Division of Research, Kaiser Permanente, Oakland, CA 94612, USA
    Am J Manag Care 13:408-16. 2007
  5. ncbi Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system
    Michele M Spence
    Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, California 90242, USA
    Pharmacotherapy 32:981-7. 2012
  6. ncbi Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit
    Michele M Spence
    Kaiser Permanente, 12254 Bellflower Blvd, Downey, CA 90242, USA
    J Manag Care Pharm 12:377-82. 2006
  7. ncbi Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug
    T Craig Cheetham
    Pharmacy Analytic Service, Kaiser Permanente Southern California, Downey, California 90242, USA
    Am J Manag Care 11:546-52. 2005
  8. ncbi Antihypertensive drugs and lip cancer in non-Hispanic whites
    Gary D Friedman
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    Arch Intern Med 172:1246-51. 2012
  9. ncbi Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid
    Michele M Spence
    Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, CA, USA
    Ann Pharmacother 44:1384-8. 2010
  10. ncbi Association between exposure to topical tacrolimus or pimecrolimus and cancers
    Rita L Hui
    Pharmacy Outcomes Research Group, Kaiser Permanente Medical Care Program, Oakland, CA, USA
    Ann Pharmacother 43:1956-63. 2009

Detail Information

Publications19

  1. ncbi Differential association between statin exposure and elevated levels of creatine kinase
    James Chan
    Pharmacy Outcomes Research Group, Pharmacy Operations, Kaiser Permanente Medical Care Program, Oakland, CA 94612 3429, USA
    Ann Pharmacother 39:1611-6. 2005
    ..Although hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are generally well tolerated, myopathy can be a serious adverse event. The association among different statins, doses, and related risk factors is not well understood...
  2. ncbi Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population
    James Chan
    Pharmacy Outcomes Research Group, Pharmacy Operations, Kaiser Permanente Medical Care Program, Oakland, Calif 94612, USA
    Am J Manag Care 10:433-41. 2004
    ....
  3. ncbi Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids
    James Chan
    Pharmacy Outcomes Research Group, Kaiser Permanente Medical Care Program, 1800 Harrison, 13th Fl, Oakland, CA 94612, USA
    J Manag Care Pharm 13:21-7. 2007
    ....
  4. ncbi Effect of cost-sharing changes on self-monitoring of blood glucose
    Andrew J Karter
    Division of Research, Kaiser Permanente, Oakland, CA 94612, USA
    Am J Manag Care 13:408-16. 2007
    ..To study the effect of cost-sharing policy changes on utilization of test strips for self-monitoring of blood glucose...
  5. ncbi Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system
    Michele M Spence
    Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, California 90242, USA
    Pharmacotherapy 32:981-7. 2012
    ..To evaluate clinical and safety outcomes among transplant recipients whose tacrolimus was converted from the brand-name formulation to a generic formulation...
  6. ncbi Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit
    Michele M Spence
    Kaiser Permanente, 12254 Bellflower Blvd, Downey, CA 90242, USA
    J Manag Care Pharm 12:377-82. 2006
    ..Generic-only pharmacy benefits may present more of a burden to patients with chronic disease conditions such as chronic obstructive pulmonary disease (COPD), where generic drug therapy choices are more limited...
  7. ncbi Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug
    T Craig Cheetham
    Pharmacy Analytic Service, Kaiser Permanente Southern California, Downey, California 90242, USA
    Am J Manag Care 11:546-52. 2005
    ..To evaluate the safety and effectiveness of a simvastatin-to-lovastatin therapeutic conversion program...
  8. ncbi Antihypertensive drugs and lip cancer in non-Hispanic whites
    Gary D Friedman
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    Arch Intern Med 172:1246-51. 2012
    ..In this study, we further characterized the risk of lip cancer associated with these and other commonly used antihypertensive drugs...
  9. ncbi Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid
    Michele M Spence
    Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, CA, USA
    Ann Pharmacother 44:1384-8. 2010
    ..There have been no head-to-head clinical trials comparing pamidronate and zoledronic acid among patients with advanced prostate cancer...
  10. ncbi Association between exposure to topical tacrolimus or pimecrolimus and cancers
    Rita L Hui
    Pharmacy Outcomes Research Group, Kaiser Permanente Medical Care Program, Oakland, CA, USA
    Ann Pharmacother 43:1956-63. 2009
    ..The Food and Drug Administration has issued a public health advisory regarding cancer risk from topical calcineurin inhibitors...
  11. ncbi Longitudinal study of new and prevalent use of self-monitoring of blood glucose
    Andrew J Karter
    Division of Research, Kaiser Permanente, Oakland, CA 94612, USA
    Diabetes Care 29:1757-63. 2006
    ..We sought to assess longitudinal association between self-monitoring of blood glucose (SMBG) and glycemic control in diabetic patients from an integrated health plan (Kaiser Permanente Northern California)...
  12. ncbi The comparative effectiveness of mail order pharmacy use vs. local pharmacy use on LDL-C control in new statin users
    Julie A Schmittdiel
    Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
    J Gen Intern Med 26:1396-402. 2011
    ..Previous studies have shown that mail order pharmacy use is associated with greater medication adherence; however, no studies have examined whether mail order pharmacy use is related to improved CVD risk factor outcomes...
  13. ncbi Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened
    Gary D Friedman
    Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Oakland, CA 94612, USA
    Cancer Causes Control 20:1821-35. 2009
    ..To screen commonly used prescription drugs for possible carcinogenic effects...
  14. ncbi Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women
    Gary D Friedman
    Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Oakland, CA 94612, USA
    Cancer Epidemiol Biomarkers Prev 15:2102-6. 2006
    ....
  15. ncbi Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity
    Gary D Friedman
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA 94612, USA
    Int J Cancer 125:2173-8. 2009
    ..Although not definitive, these findings should be considered in the evaluations of these pharmaceuticals...
  16. ncbi Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients
    Gary D Friedman
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
    Pharmacoepidemiol Drug Saf 17:27-36. 2008
    ..Determine the risk of cancer in statin users...
  17. ncbi Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide
    Eric J Ip
    Department of Clinical Sciences, Touro University College of Pharmacy, Vallejo, CA 94592, USA
    Am J Health Syst Pharm 65:1552-5. 2008
    ....
  18. ncbi Erratum: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients
    Gary D Friedman
    Pharmacoepidemiol Drug Saf 17:751. 2008
  19. ncbi Functional outcomes following chemoradiotherapy for head and neck cancer
    Lee M Akst
    Department of Otolaryngology and Communicative Disorders, The Cleveland Clinic Foundation, Ohio 44195, USA
    Otolaryngol Head Neck Surg 131:950-7. 2004
    ..To study functional outcomes following concurrent chemoradiotherapy of head and neck cancer...